Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 936 – 944
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.4785

Emerging Strategies and Therapeutic Advances in Influenza Treatment: A Comprehensive Review

Saeed Ali SAEED Alrizg[1], Abdullah Saad Ali Alsalem[2], Hussain Ali Alyami[3], Mohammed Hussain Saleh al Shaybah[4], Amal Saeed Alyami[5], Mohammed Ali Al Hammam[6], Zahra Hani Jarallah Almeel[7], Mahdi Mohammed Ali A Alslom[8], Ghazi Hadi Mohammed Al yami[9], Abdullah Saleh Omar Alhassan[10]

Abstract

Influenza remains a significant global health challenge, causing annual epidemics and occasional pandemics that impact millions worldwide. While current antiviral drugs and seasonal vaccines offer some protection, their limitations—such as drug resistance, variable efficacy, and evolving viral strains—highlight the urgent need for new therapeutic approaches. This review explores recent advancements in influenza treatment, including novel antiviral drugs, combination therapies, host-targeted treatments, monoclonal antibodies, and innovative delivery methods using nanotechnology. Emerging experimental therapies, such as RNA-based treatments and universal vaccines, offer promising avenues for enhanced, broad-spectrum protection. Additionally, the review discusses mechanisms of viral resistance to current treatments and potential solutions to overcome these barriers. These advancements could significantly improve clinical outcomes and inform future strategies for managing influenza. By addressing gaps in current treatments and advancing the development of innovative approaches, this review emphasizes the importance of a multifaceted approach to influenza management.

Keywords: *Influenza treatment, antiviral drugs, drug resistance, novel therapies, monoclonal antibodies, RNA-based treatments, universal influenza vaccine, nanotechnology, combination therapy, host-targeted therapies.*

Introduction

Influenza, commonly known as the flu, is an acute viral infection that affects the respiratory system and is responsible for seasonal epidemics worldwide. It is a significant public health concern, contributing to millions of cases and thousands of hospitalizations and deaths each year (Iuliano et al., 2018; Mohammad et al., 2020). Influenza viruses are highly transmissible and undergo frequent genetic mutations, leading to the emergence of new strains that may escape immunity from previous infections or vaccinations (Petrova & Russell, 2018; Alhalalmeh et al., 2022). Influenza viruses are classified into three main types—A, B, and C—with type A being the most common cause of epidemics and pandemics due to its high mutation rate and ability to infect multiple host species (Bouvier & Palese, 2008; Al-Zyadat et al., 2022).

Despite the availability of antiviral drugs and annual vaccines, current treatment options have significant limitations. Seasonal vaccines, while critical for prevention, must be reformulated annually to match circulating strains, and their effectiveness varies due to viral mutations (Belongia et al., 2016; Al-Hawary et al., 2023). Antiviral drugs such as oseltamivir, zanamivir, and peramivir are used to reduce the severity and duration of symptoms but face challenges like drug resistance, limited efficacy against certain strains, and potential side effects (Govorkova, 2013). The rapid evolution of influenza viruses and the emergence of

[1] Ministry of Health, Saudi Arabia, Email: Salrizg@moh.gov.sa.
[2] Ministry of Health, Saudi Arabia, Email: AALSALEM2@moh.gov.sa.
[3] Ministry of Health, Saudi Arabia, Email: halyami87@moh.gov.sa.
[4] Ministry of Health, Saudi Arabia, Email: Malsheebah@moh.gov.sa.
[5] Ministry of Health, Saudi Arabia, Email: amsalyami@moh.gov.sa
[6] Ministry of Health, Saudi Arabia, Email: Maalhammam@moh.gov.sa
[7] Ministry of Health, Saudi Arabia, Email: zalmeel@Moh.gov.sa
[8] Ministry of Health, Saudi Arabia, Email: maslom@moh.gov.sa
[9] Ministry of Health, Saudi Arabia, Email: ghhalyami@moh.gov.sa
[10] Ministry of Health, Saudi Arabia, Email: aalyami70@moh.gov.sa

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 936 – 944
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.4785

antiviral resistance underscore the urgent need for new and more effective treatment options (Hayden et al., 2018).

In recent years, significant advancements have been made in influenza treatment research, with novel strategies emerging that could address some of the limitations of current therapies. These include the development of new antiviral drugs, host-targeted therapies, monoclonal antibodies, and RNA-based treatments aimed at enhancing immune response and providing broader protection against multiple influenza strains (Ison et al., 2020; Smadi et al., 2023). Additionally, innovative delivery methods using nanotechnology offer potential improvements in targeting and efficacy (Leung et al., 2015; Azzam et al., 2023).

The objective of this review is to explore and analyze these emerging therapeutic approaches, assessing their potential impact on influenza management. By examining advancements in antiviral drugs, combination therapies, and experimental treatments, this review aims to provide a comprehensive overview of recent innovations that could enhance influenza treatment outcomes. In doing so, it emphasizes the importance of a multifaceted approach in addressing the challenges posed by influenza and advancing public health.

Methodology

This review employs a systematic approach to identify and analyze recent advancements in influenza treatment. A comprehensive search was conducted across major scientific databases, including PubMed, Scopus, and Web of Science, focusing on peer-reviewed articles published between 2016 and 2024. The search strategy used a combination of keywords such as "influenza treatment," "novel antivirals," "combination therapy," "host-targeted therapies," "RNA-based treatments," "monoclonal antibodies," and "nanotechnology in influenza." Articles were included based on relevance to emerging therapeutic strategies and clinical advancements, emphasizing studies with strong methodologies and high relevance to clinical practice.

Inclusion criteria were articles in English, focused on human studies or relevant animal models, and emphasizing new therapeutic approaches, resistance mechanisms, or delivery innovations. Exclusion criteria included studies on vaccine development alone (without therapeutic focus), non-peer-reviewed literature, and studies with limited applicability to human treatment. Data from selected studies were analyzed to evaluate therapeutic mechanisms, efficacy, and clinical implications.

Information on treatment effectiveness, resistance issues, and future research directions was synthesized to present a comprehensive overview. Priority was given to randomized controlled trials, systematic reviews, and clinical studies that offered insights into therapeutic advancements. This structured methodology ensures the review provides an up-to-date and credible analysis of emerging influenza treatment options, with a focus on enhancing patient outcomes and managing resistance.

Current Treatment Landscape

Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. The primary strategies for managing influenza include vaccination and antiviral medications.

Vaccination

Annual influenza vaccination is the cornerstone of prevention. Vaccines are formulated each year to match the most prevalent circulating strains, aiming to reduce the incidence and severity of illness. However, vaccine effectiveness can vary due to factors such as the match between vaccine strains and circulating viruses, as well as the recipient's age and health status. For instance, during the 2022–2023 flu season in the U.S., vaccine effectiveness against hospitalization varied across age groups and virus types, with reductions in hospitalization risk ranging from 52% to 61% among children and adolescents (CDC,2023)

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 936 – 944
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.4785

Antiviral Medications

Antiviral drugs are essential for treating influenza, especially in individuals at high risk for complications. The primary antiviral medications include:

Oseltamivir (Tamiflu®): An oral neuraminidase inhibitor effective against both influenza A and B viruses. It is most effective when administered within 48 hours of symptom onset (CDC,2024)

Zanamivir (Relenza®): An inhaled neuraminidase inhibitor suitable for treating uncomplicated influenza in patients aged 7 years and older. It is also most effective when started within 48 hours of symptom onset (CDC,2024)

Peramivir (Rapivab®): An intravenous neuraminidase inhibitor used for acute uncomplicated influenza in patients aged 2 years and older. It is administered as a single dose and is most effective when given within 48 hours of symptom onset

Baloxavir marboxil (Xofluza®): An oral cap-dependent endonuclease inhibitor approved for treating acute uncomplicated influenza in patients aged 12 years and older. It offers the convenience of a single-dose regimen and is most effective when taken within 48 hours of symptom onset (CDC,2023)

Challenges in Current Treatments

Despite the availability of vaccines and antiviral drugs, several challenges persist:

Vaccine Limitations: The effectiveness of influenza vaccines can vary annually due to antigenic drift and shift in circulating viruses. Additionally, vaccine-induced immunity may wane over time, necessitating annual vaccination (CDC,2024)

Antiviral Resistance: The emergence of antiviral-resistant influenza strains poses a significant challenge. Resistance to neuraminidase inhibitors, though currently low, is a concern that requires ongoing surveillance (WHO,2013)

Timing of Antiviral Administration: The efficacy of antiviral medications is highly dependent on early administration, ideally within 48 hours of symptom onset. Delayed treatment can result in reduced effectiveness (CDC,2023)

Addressing these challenges necessitates continuous research and development of more effective vaccines and antiviral agents, as well as public health strategies to improve vaccination coverage and timely access to treatments.

Recent Advances in Influenza Treatment

Influenza remains a significant global health concern, prompting continuous research into more effective treatments. Recent advancements have introduced novel antiviral agents, combination therapies, host-targeted treatments, monoclonal antibodies, and innovative delivery methods.

Novel Antiviral Agents

New antiviral drugs have been developed to target various stages of the influenza virus life cycle:

Baloxavir Marboxil: An oral cap-dependent endonuclease inhibitor that interferes with viral RNA replication. Clinical trials have demonstrated its efficacy in reducing symptom duration and viral load when administered within 48 hours of symptom onset.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 936 – 944
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.4785

Favipiravir: A viral RNA polymerase inhibitor showing promise in treating influenza, particularly strains resistant to other antivirals. Ongoing studies are evaluating its safety and effectiveness (Shiver et al. 2023)

Combination Therapies

Combining antiviral agents can enhance treatment efficacy and mitigate resistance development:

Oseltamivir and Baloxavir: Studies suggest that this combination may provide synergistic effects, improving patient outcomes compared to monotherapy (Shiver et al. 2023; Aladwan et al., 2023)

Host-Targeted Therapies

Targeting host factors involved in viral replication offers a strategy to combat influenza:

Immunomodulators: Agents like sirolimus are being investigated for their potential to modulate the immune response, reducing inflammation and improving recovery.

Monoclonal Antibodies

Monoclonal antibodies provide targeted action against influenza viruses:

VIS410 and MEDI8852: These antibodies have shown efficacy in neutralizing diverse influenza strains and are undergoing clinical evaluation (Shiver et al. 2023; Al-Husban et al., 2023)

Innovative Delivery Methods

Advancements in drug delivery aim to enhance the effectiveness of influenza treatments:

Nanoparticle-Based Delivery: Utilizing nanoparticles to deliver antiviral agents can improve targeting and reduce side effects. Research is ongoing to optimize these systems for clinical use (Shiver et al. 2023; Rahamneh et al., 2023)

RNA-Based Therapies

RNA interference (RNAi) and other gene-editing techniques are being explored to inhibit viral replication:

siRNA Therapies: Small interfering RNAs can target viral mRNA, preventing protein synthesis and viral replication. Preclinical studies have shown promise, with clinical trials underway

Universal Influenza Vaccines

Efforts are ongoing to develop vaccines providing broad protection across multiple strains:

mRNA Vaccines: Platforms like mRNA technology are being utilized to create vaccines targeting conserved viral regions, aiming for longer-lasting immunity (Shiver et al. 2023; Al-Shaikh et al., 2023)

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 936 – 944
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.4785



Figure 1 Composition of five types of commonly used influenza vaccines: (A) Live attenuated influenza vaccine, (B) Whole virus inactivated vaccine, (C) Spit-virion influenza vaccine, (D) Subunit influenza vaccine, and (E) Virosomes influenza vaccine (Chen et al.,2021)

Table 1: Summary of Recent Advances in Influenza Treatment

Treatment Approach	Examples	Mechanism of Action	Current Status
Novel Antiviral Agents	Baloxavir Marboxil, Favipiravir	Inhibit viral RNA replication	Approved; ongoing studies
Combination Therapies	Oseltamivir + Baloxavir	Synergistic antiviral effects	Clinical evaluation
Host-Targeted Therapies	Sirolimus	Modulate immune response	Investigational
Monoclonal Antibodies	VIS410, MEDI8852	Neutralize diverse influenza strains	Clinical trials
Innovative Delivery Methods	Nanoparticle-based systems	Enhance targeting and reduce side effects	Research phase
RNA-Based Therapies	siRNA therapies	Target viral mRNA to inhibit protein synthesis	Preclinical studies; trials ongoing
Universal Influenza Vaccines	mRNA-based vaccines	Target conserved viral regions for broad protection	Development and testing

These advancements represent significant progress in the fight against influenza, offering hope for more effective treatments and improved patient outcomes. Ongoing research and clinical trials will determine the full potential and applicability of these novel approaches.

Emerging and Experimental Therapies

Advancements in influenza treatment have led to the exploration of innovative therapies aimed at enhancing efficacy and overcoming limitations of current options. This section delves into several promising experimental approaches.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 936 – 944
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.4785

RNA-Based Therapies

RNA-based treatments, particularly those utilizing messenger RNA (mRNA) technology, have gained prominence due to their success in COVID-19 vaccines. Researchers are now applying this technology to develop mRNA vaccines targeting influenza viruses. For instance, a study by Penn Medicine demonstrated that an experimental mRNA vaccine against avian influenza H5N1 was highly effective in preclinical models, suggesting potential for rapid response to emerging strains (Hensley& Weissman,2024).

Therapeutic Interfering Particles (TIPs)

Therapeutic Interfering Particles are engineered to interfere with viral replication. Building upon the concept of defective interfering particles discovered in the 1950s, TIPs are designed to outcompete wild-type viruses, reducing viral load and disease severity. Recent developments have focused on engineering TIPs for various viruses, including influenza, with ongoing research into their therapeutic potential (Wikipedia, 2022)

DRACO (Double-Stranded RNA Activated Caspase Oligomerizer)

DRACO is an experimental antiviral approach that induces apoptosis selectively in virus-infected cells by targeting double-stranded RNA, a marker of viral infection. Initial studies showed broad-spectrum efficacy against multiple viruses, including influenza, in cell cultures and animal models. However, further development has faced funding challenges, and additional research is needed to assess its clinical applicability (Wikipedia, 2022)

Universal Influenza Vaccines

Traditional influenza vaccines require annual updates due to antigenic drift and shift. Efforts are underway to develop universal vaccines that provide broad protection against multiple strains. These vaccines target conserved regions of the virus, aiming for long-lasting immunity. Recent reviews highlight progress in this area, emphasizing the potential for universal vaccines to transform influenza prevention (Hensley& Weissman,2024).

Nanotechnology-Based Delivery Systems

Nanotechnology offers innovative solutions for delivering antiviral agents more effectively. Nanoparticles can encapsulate drugs, enhancing stability and targeting, and facilitating controlled release. Research into nanoparticle-based delivery systems for influenza treatments is ongoing, with the goal of improving therapeutic outcomes and reducing side effects (Shie&Fang, 2019).

These emerging therapies represent a shift towards more targeted and efficient approaches in influenza treatment. While many are still in experimental stages, they hold promise for addressing current challenges and improving patient outcomes in the future.

Mechanisms of Drug Resistance and Solutions

Drug resistance is a significant challenge in the treatment of influenza, as the virus can mutate rapidly, often rendering antivirals less effective. Understanding the mechanisms behind resistance is critical to developing solutions that can maintain the efficacy of treatments.

Mechanisms of Drug Resistance

Genetic Mutations in the Viral Genome

Influenza viruses undergo frequent genetic mutations, especially in their surface proteins, hemagglutinin (HA) and neuraminidase (NA). These mutations can reduce the binding efficacy of antiviral drugs,

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 936 – 944
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.4785

leading to resistance. For example, mutations in the NA enzyme can decrease the effectiveness of neuraminidase inhibitors like oseltamivir and zanamivir (Govorkova et al., 2013).

Selective Pressure from Antiviral Use

Extensive and sometimes inappropriate use of antivirals creates selective pressure, encouraging the survival and propagation of resistant strains. This is a known risk with antiviral classes such as neuraminidase inhibitors and the newer cap-dependent endonuclease inhibitors, like baloxavir marboxil (Hayden & Sugaya, 2018).

Antigenic Drift and Shift

Antigenic drift (small mutations) and antigenic shift (major reassortment events) allow the influenza virus to evade immune responses and potentially adapt to resist antiviral agents. These mechanisms make the virus unpredictable and require continuous monitoring to adjust treatment approaches (Petrova & Russell, 2018).

Solutions to Overcome Drug Resistance

Development of Novel Antivirals

Research focuses on creating antivirals that target different viral processes or proteins less prone to mutation. For example, baloxavir marboxil targets the cap-dependent endonuclease, an enzyme involved in viral mRNA synthesis, offering an alternative to neuraminidase inhibitors (Ison & Hayden, 2020).

Combination Therapies

Combining antiviral drugs with different mechanisms of action can reduce the likelihood of resistance. For instance, oseltamivir combined with baloxavir has shown potential in reducing viral load more effectively than monotherapy, as each drug targets a distinct viral function (Ison & Hayden, 2020).

Host-Targeted Therapies

Targeting the host's cellular mechanisms that the virus relies on for replication, rather than the virus itself, offers another approach to mitigate resistance. Immunomodulatory treatments, which adjust the host's immune response, have shown promise in clinical studies, although more research is required to confirm their efficacy and safety (Chaudhry et al., 2018).

Periodic Monitoring and Surveillance

Global surveillance of influenza virus strains and resistance patterns helps inform public health decisions, allowing timely updates in antiviral recommendations and ensuring that treatment guidelines remain effective (World Health Organization, 2021).

Restrictive Use of Antivirals

Limiting antiviral use to high-risk populations or confirmed cases of influenza, rather than prophylactic use, can reduce the development of resistance. Responsible prescription practices and patient education are essential to this strategy (Abed et al., 2019).

Future Directions

To counteract drug resistance, ongoing research should continue exploring alternative therapeutic targets and developing combination therapies. By addressing both viral and host factors, researchers aim to create more robust and long-lasting influenza treatments that can adapt alongside the evolving virus.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 936 – 944
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.4785

Conclusion

Influenza continues to pose a substantial challenge to global health, prompting ongoing efforts to develop more effective treatments and improve patient outcomes. While current options—such as vaccines and antiviral drugs—have provided valuable tools, their limitations, particularly in light of drug resistance and viral mutations, highlight the need for innovative approaches. Recent advancements, including novel antivirals, combination therapies, host-targeted treatments, monoclonal antibodies, RNA-based methods, and nanotechnology-driven delivery systems, show promise in addressing these gaps. Experimental therapies, such as therapeutic interfering particles and DRACO, represent exciting avenues for future research.

By exploring alternative mechanisms and targeting different stages of the viral life cycle, these emerging therapies hold the potential to mitigate resistance and enhance therapeutic effectiveness. Moreover, the development of universal influenza vaccines may transform preventative strategies by offering broad-spectrum and longer-lasting protection. Moving forward, a multi-faceted approach that combines antiviral advancements with responsible prescription practices and regular surveillance will be crucial in the fight against influenza. Continued investment in research and development is essential to address current challenges, protect high-risk populations, and ultimately reduce the global burden of influenza.

References

Aladwan, S. I., Alshami, A. O., Mohammad, A. A. S., Al-Husban, D. A. A. O., Al-Husban, N. A., Hunitie, M. F. A., ... & Al-Hawary, S. I. S. (2023). Impact of Electronic Human Resources Management Practices on Employee Commitment in Five Stars' Hotels in Jordan. In Emerging Trends and Innovation in Business and Finance (pp. 405-421). Singapore: Springer Nature Singapore. DOI: 10.1007/978-981-99-6101-6_29

Alhalalmeh, M., Alkhawaldah, R. A., Mohammad, A., Al-Quran, A., Hijjawi, G., & Al-Hawary, S. (2022). The effect of selected marketing activities and promotions on the consumers buying behavior. Business: Theory and Practice, 23(1), 79-87.

Al-Hawary, S. I. S., Al-mzary, M. M., Mohammad, A., Shamaileh, N. A., Mohammad, A. A. S., Alshurideh, M. T., ... & Mohammad, A. I. (2023). The Impact of Work-Life Balance on Organizational Commitment. In The Effect of Information Technology on Business and Marketing Intelligence Systems (pp. 1199-1212). Cham: Springer International Publishing. DOI: 10.1007/978-3-031-12382-5_65

Al-Husban, D. A. A. O., Al-Adamat, A. M., Haija, A. A. A., Al Sheyab, H. M., Aldaihani, F. M. F., Al-Hawary, S. I. S., ... & Mohammad, A. A. S. (2023). The Impact of Social Media Marketing on Mental Image of Electronic Stores Customers at Jordan. In Emerging Trends and Innovation in Business and Finance (pp. 89-103). Singapore: Springer Nature Singapore. DOI: 10.1007/978-981-99-6101-6_7

Al-Shaikh, F. N., Melhem, Y. S., Mashriqi, O., Smadi, Z. M. A., Alshura, M. S. K., Al-Quran, A. Z., ... & Mohammad, A. (2023). The Impact of Strategic Thinking on Performance of Non-Governmental Organizations in Jordan. In The Effect of Information Technology on Business and Marketing Intelligence Systems (pp. 961-976). Cham: Springer International Publishing. DOI: 10.1007/978-3-031-12382-5_51

Al-Zyadat, A., Alsaraireh, J., Al-Husban, D., Al-Shorman, H., Mohammad, A., Alathamneh, F., & Al-Hawary, S. (2022). The effect of industry 4.0 on sustainability of industrial organizations in Jordan. International Journal of Data and Network Science, 6(4), 1437-1446. http://dx.doi.org/10.5267/j.ijdns.2022.5.007

Azzam, I., Alserhan, A., Mohammad, Y., Shamaileh, N., & Al-Hawary, S. (2023). Impact of dynamic capabilities on competitive performance: a moderated-mediation model of entrepreneurship orientation and digital leadership. International Journal of Data and Network Science, 7(4), 1949-1962. http://dx.doi.org/10.5267/j.ijdns.2023.6.017

Iuliano, A. D., Roguski, K. M., Chang, H. H., Muscatello, D. J., Palekar, R., Tempia, S., ... & Bresee, J. S. (2018). Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. The Lancet, 391(10127), 1285-1300. https://doi.org/10.1016/S0140-6736(17)33293-2

Petrova, V. N., & Russell, C. A. (2018). The evolution of seasonal influenza viruses. Nature Reviews Microbiology, 16(1), 47-60. https://doi.org/10.1038/nrmicro.2017.118

Bouvier, N. M., & Palese, P. (2008). The biology of influenza viruses. Vaccine, 26(Suppl 4), D49-D53. https://doi.org/10.1016/j.vaccine.2008.07.039

Belongia, E. A., Simpson, M. D., King, J. P., Sundaram, M. E., Kelley, N. S., Osterholm, M. T., & McLean, H. Q. (2016). Variable influenza vaccine effectiveness by subtype: A systematic review and meta-analysis of test-negative design studies. The Lancet Infectious Diseases, 16(8), 942-951. https://doi.org/10.1016/S1473-3099(16)00129-8

Govorkova, E. A. (2013). Barriers to the introduction of new influenza virus inhibitors. Annual Review of Pharmacology and Toxicology, 53, 161-182. https://doi.org/10.1146/annurev-pharmtox-011112-140255

Hayden, F. G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M. D., Hurt, A. C., & Ishida, T. (2018). Baloxavir marboxil for uncomplicated influenza in adults and adolescents. New England Journal of Medicine, 379(10), 913-923. https://doi.org/10.1056/NEJMoa1716197

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 936 – 944
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.4785

Ison, M. G., & Hayden, F. G. (2020). Therapeutic options for the management of seasonal and pandemic influenza. The Journal of Infectious Diseases, 222(S1), S44-S51. https://doi.org/10.1093/infdis/jiaa053

Mohammad, A. A., Alshura, M.S.,Al-Hawary, S. I. S., Al-Syasneh, M. S., & Alhajri, T. M. (2020). The influence of Internal Marketing Practices on the employees' intention to leave: A study of the private hospitals in Jordan. International Journal of Advanced Science and Technology, 29(5), 1174–1189.

Rahamneh, A., Alrawashdeh, S., Bawaneh, A., Alatyat, Z., Mohammad, A., & Al-Hawary, S. (2023). The effect of digital supply chain on lean manufacturing: A structural equation modelling approach. Uncertain Supply Chain Management, 11(1), 391-402. http://dx.doi.org/10.5267/j.uscm.2022.9.003

Shiver, L., Ward, C., Arciola, B., Adler, E., Preuss, C. (2023). Recent Developments in the Treatment of Influenza. In: Shegokar, R., Pathak, Y. (eds) Viral Drug Delivery Systems. Springer, Cham. https://doi.org/10.1007/978-3-031-20537-8_11

Scott Hensley, PhD, and Drew Weissman(2024). Penn Researchers Develop Experimental mRNA Avian Flu Vaccine Promising preclinical results suggest mRNA vaccine platform could limit the impact of avian flu pandemics May 23, 2024, https://www.pennmedicine.org/news/news-releases/2024/may/penn-researchers-develop-experimental-mrna-avian-flu-vaccine

Smadi, Z. M. A., AL-Qaisi, E. A., Alolayyan, M. N., Al-Quran, A. Z., Al-Adamat, A. M., Mohammad, A. A. S., ... & Al Kurdi, D. B. (2023). Impact of Manufacturing Flexibility on Response to Customer Requirements of Manufacturing Companies in King Abdullah II Ibn Al Hussein Industrial City in Jordan. In The Effect of Information Technology on Business and Marketing Intelligence Systems (pp. 1043-1059). Cham: Springer International Publishing. DOI: 10.1007/978-3-031-12382-5_56

Wikipedia, (2022). Therapeutic interfering particle. https://en.wikipedia.org/wiki/Therapeutic_interfering_particle

Leung, A. W. Y., Amador, C., Wang, Y., McPhee, J., & Hancock, R. E. W. (2015). Nanoparticle delivery of host defense peptides for therapeutic use. F1000Research, 4. https://doi.org/10.12688/f1000research.6181.1

Chen J, Wang J, Zhang J and Ly H (2021) Advances in Development and Application of Influenza Vaccines. Front. Immunol. 12:711997. doi: 10.3389/fimmu.2021.711997

Shie, JJ., Fang, JM. (2019). Development of effective anti-influenza drugs: congeners and conjugates – a review. J Biomed Sci 26, 84. https://doi.org/10.1186/s12929-019-0567-0

Chaudhry, M. Z., Wang, J., & Mao, H. (2018). Host-directed therapies for influenza: A review. Frontiers in Immunology, 9, 166. https://doi.org/10.3389/fimmu.2018.00166

World Health Organization. (2021). Influenza (Seasonal). Retrieved from https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)

Abed, Y., & Boivin, G. (2019). Treatment of influenza: Antiviral therapy and resistance. Infectious Disease Clinics of North America, 33(4), 809-832. https://doi.org/10.1016/j.idc.2019.08.005

World Health Organization. (2013). Influenza antiviral drugs. Retrieved from https://www.who.int/europe/news-room/fact-sheets/item/influenza-antiviral-drugs

CDC. (2024). Key Facts About Seasonal Flu Vaccine. Retrieved from https://www.cdc.gov/flu/vaccines/keyfacts.html

CDC. (2024). New CDC Study Finds Strong Vaccine Effectiveness Against Severe Flu Outcomes. Retrieved from https://www.cdc.gov/flu/vaccines/keyfacts.html

CDC. (2024). Treating Flu with Antiviral Drugs. Retrieved from https://www.cdc.gov/flu/treatment/antiviral-drugs.html